Compare Eli Lilly And Co (LLY) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Simon Property Group Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Simon Property Group Inc trades at $199.42 (market cap $64.59B). The key difference: Eli Lilly And Co is far larger — about 16.1× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Simon Property Group Inc for 99 Days on average.
| LLY | SPG | |
|---|---|---|
Market Cap | $1.04T | $64.59B |
Volume | 3,064,878 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $1.28K | $236.70 |
52-Week Low | $799.57 | $173.35 |
Typical Hold Time | 93 Days | 99 Days |
Enterprise Value | $1.09T | $93.03B |
Dividend Yield | 0.59% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Simon Property Group (SPG) trades at $199.61, up 1.02% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results, including revenue of $6.36B and net income of $4.63B, with a net margin of 72.7%. Recent news highlights leasing demand strength and a new media network launch, while analysts maintain a consensus price target of $222.90.
SPG offers value with a P/E of 14.09 and robust profitability, but faces risks from high debt levels and interest rate sensitivity. The stock's upside potential hinges on sustained retail demand and effective debt management, with institutional sentiment leaning neutral amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
